We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of IsoPlexis Corporation (“IsoPlexis” or the “Company”) (NASDAQ: ISO) in connection with its proposed acquisition by Berkeley Lights, Inc. (“Berkeley Lights”) (NASDAQ: BLI). Under the merger agreement, the Company’s shareholders will receive 0.612 shares of Berkeley Lights common stock for each IsoPlexis share, representing implied per-share consideration of $1.44 based upon Berkeley Lights’ February 2, 2023 closing price of $2.36. Upon completion of the transaction, Berkeley Lights shareholders will own 75.2% of the combined company, while IsoPlexis shareholders will only own 24.8% of the combined company. The transaction is valued at approximately $57.8 million.
Weiss Law is investigating whether (i) IsoPlexis’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction, (ii) the merger consideration adequately compensates IsoPlexis shareholders, and (iii) all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.
September 26, 2023
We are investigating possible breaches of fiduciary duty and violations of the federal securities laws by, among others, the Board of Directors and senior officers of Origin Materials, Inc. (NASDAQ: ORGN) (“Origin” or the “Company”), concerning the Company’s business, operations, and prospects surrounding the construction of the Origin 2 commercial plant.
September 14, 2023
Weiss Law announces that on September 13, 2023, they filed a class action lawsuit in the United States District Court for the Southern District of New York (“Court”), captioned Zappia v. Myovant Sciences Ltd. et al. Case 1:23-cv-08097, on behalf of a class (“Class”) of individuals and entities that held common stock of Myovant Sciences, Ltd. (“Myovant”) as of the close of business on January 20, 2023 (“Class Period”), asserting claims under Sections 14(a) and 20(a) of the Securities Exchange Act of 1934, and Securities and Exchange Commission Rule 14a-9, in connection with the acquisition of Myovant Sciences, Ltd. by Sumitovant Biopharma Ltd. for an unfair price.
September 11, 2023
We are investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Hostess Brands, Inc. (“Hostess” or the “Company”) (NASDAQ: TWNK), in connection with its acquisition by The J. M. Smucker Company (NYSE: SJM) (“Smucker”) via tender offer.